News

January 21, 2026

Odyssey Therapeutics Appoints Jolie M. Siegel as Executive Vice President, General Counsel

November 11, 2025

Odyssey Therapeutics Appoints Dennis Dean, Ph.D., as Executive Vice President, Head of Non-Clinical Development

October 9, 2025

Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to its Board of Directors      

September 10, 2025

Odyssey Therapeutics Announces Oversubscribed $213 Million Series D Financing to Advance Clinical Pipeline for Autoimmune Diseases

January 8, 2025

Odyssey Therapeutics Appoints Jason Haas as Chief Financial Officer